65,437 trials
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 (ADHD-RS-5) Total Score — -14.2; -12.1 units on a scale
Dry Eye
Primary: Total Corneal Fluorescein Staining — 4.09; 5.05 units on a scale
Cystic Fibrosis · Allergic Bronchopulmonary Aspergillosis
Primary: Number of Participants With Aspergillus Induced IL-13 Responses in CD4+ T-cells — 7 Participants
Opioid Use Disorder · Opioid-related Disorders
Primary: Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period — 302; 145; 172; 61 Participants
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
Cocaine Dependence
Primary: Cocaine Use Based on Urine Drug Screening — 20.36; 15.57; 22.3; 27.8 number of negative drug screens
Septic Shock · Fluid Therapy · Hypotension
Primary: Cumulative Fluid Administered — 4417; 4110 mL of study fluid
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 1.68; 2.66 units on a scale
Alcohol Abuse
Primary: Alcohol Abstinence — 2.9; 2.6 Samples — p=0.66
Presbyopia
Primary: Number of Participants With Improvement in Uncorrected Near Visual Acuity (20/40 or Better) in the Implanted Eye — 336 Count of Participants
Leukemia · Lymphoma
Primary: Objective Response Rate — 2; 4; 6; 17 Participants
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Type 1 Diabetes Mellitus
Primary: Adjusted Mean Change in HbA1c From Baseline at Week 24 — -0.45; -0.47; -0.03 Percentage of hemoglobin — p=<0.0001
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR12) — 92.6; 75.0 Percentage of participants
Myotonic Dystrophy
Primary: Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance — 17.44; 7.25 Meters